Indivior (INDV) on Monday said that it will cancel its secondary listing on the London Stock Exchange, effective July 25, ...

Pharmaceutical firm Indivior has announced it will soon delist from the London Stock Exchange, keeping its primary listing on the Nasdaq.

Drug maker Indivior (INDV.L) has announced plans to delist its shares from the London Stock Exchange (LSE), marking the ...

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align ...

Drugmaker Indivior has announced plans to cancel its secondary listing in London, just a year after moving its primary ...

Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of ...

Indivior said it would cancel its listing on the London Stock Exchange and keep its primary listing on New York City's Nasdaq stock exchange.

The British pharmaceuticals company said the US exchange offers the ‘most attractive and valuable opportunity set’ ...

Drug maker Indivior has announced plans to delist its shares from the London Stock Exchange (LSE), marking the latest company ...

Indivior has planned to cancel the secondary listing of the firm’s shares on the London Stock Exchange. In a notice today (2 ...

Investing.com -- Indivior (LON: INDV) on Monday said it will delist from the London Stock Exchange (LON: LSEG) on July 25, ...